Item 1.01. Entry into a Material Definitive Agreement.
On April 18, 2023, Immuneering Corporation (the “Company”)
entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Cowen and Company, LLC and Guggenheim
Securities, LLC, as representatives of the several underwriters listed on Schedule I attached thereto (the “Underwriters”),
in connection with the public offering, issuance and sale by the Company of 2,727,273 shares of the Company’s Class A common stock,
$0.001 par value per share (the “Common Stock”), at a public offering price of $11.00 per share, less underwriting discounts
and commissions, pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-266738) and a related prospectus
supplement filed with the Securities and Exchange Commission (the “Offering”). The closing of the Offering is expected to
occur on or about April 20, 2023, subject to the satisfaction of customary closing conditions.
The Company expects to receive net proceeds from the Offering of approximately
$27.8 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company
intends to use the net proceeds of the Offering to advance the preclinical and clinical development of its product candidates and for
working capital and other general corporate purposes.
The Underwriting Agreement contains customary representations, warranties
and covenants by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including
for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations,
warranties and covenants contained in the Underwriting Agreement were made solely for the benefit of the parties thereto and may be subject
to limitations agreed upon by the contracting parties. Accordingly, the Underwriting Agreement is incorporated herein by reference only
to provide investors with information regarding the terms of the Underwriting Agreement and not to provide investors with any other factual
information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company’s periodic
reports and other filings with the Securities and Exchange Commission.
The foregoing description of the Underwriting Agreement is not complete
and is qualified in its entirety by reference to the full text of the Underwriting Agreement, a copy of which is filed as Exhibit 1.1
to this report and is incorporated by reference herein.
Latham & Watkins LLP, counsel to the Company, has issued an opinion
to the Company, dated April 19, 2023, regarding the validity of the shares of Common Stock to be issued and sold in the offering. A copy
of the opinion is filed as Exhibit 5.1 to this Current Report on Form 8-K (this “Current Report”).
Forward-Looking Statements
This Current Report contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report that do not relate to
matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the consummation
of the offering, the terms of the offering, the anticipated use of the net proceeds from the offering and the anticipated gross proceeds
and net proceeds therefrom.
These forward-looking statements are based on our current expectations
and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results
to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials, and risks related
to financial reporting.
These and other important factors discussed under the caption “Risk
Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 and filed with the U.S. Securities and Exchange
Commission (the “SEC”) on March 6, 2023 and our other reports filed with the SEC could cause actual results to differ materially
from those indicated by the forward-looking statements made in this Current Report. Any such forward-looking statements represent management’s
estimates as of the date of this Current Report. While we may elect to update such forward-looking statements at some point in the future,
we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not
be relied upon as representing our views as of any date subsequent to the date of this Current Report.